IN-VITRO EVALUATION OF CEFDINIR (FK482), A NEW ORAL CEPHALOSPORIN WITH ENHANCED ANTISTAPHYLOCOCCAL ACTIVITY AND BETA-LACTAMASE STABILITY

Cefdinir (FK482), a new oral cephalosporin with enhanced beta-lactamas e stability, was tested by microbroth dilution against respiratory, ur ogenital, and skin and skin-structure bacterial pathogens. Included we re beta-lactamase (beta LAC)-producing and -nonproducing isolates. Act ivity was compared with that of other orally administered beta-lactams . Cefdinir minimum inhibitory concentrations for 90% of isolates MIC(9 0)s (mu g/ml) were less than or equal to 0.5 versus beta LAC+/oxacilli n-susceptible Staphylococcus, aureus, S. epidermidis, and S. saprophyt icus; less than or equal to 0.06 versus Streptotoccus groups A and B, and Neisseria gonorrhoeae beta LAC+; 0.125 versus S. pneumoniae penici llin-susceptible and Proteus mirabilis beta LAC+; 0.25 versus beta LAC + versus strains of Moraxella catarrhalis, Escherichia coli, Klebsiell a pneumoniae, and K. oxytoca; 0.5 versus Haemophilus influenzae beta L AC-; 1 versus H. influenzae beta LAC+; 4 versus Legionella pneumophila beta LAC+; and 8 versus Enterococcus faecalis beta-strains. Cefdinir was equally effective against both standard and high inocula of S. aur eus strains producing A, B, C, or D beta LAC types. MICs were also gen erated versus quality-control reference strains.